Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBT Margin (2022 - 2025)

Historic EBT Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 60.53%.

  • Phathom Pharmaceuticals' EBT Margin rose 4627600.0% to 60.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 186.44%, marking a year-over-year increase of 11054300.0%. This contributed to the annual value of 605.08% for FY2024, which is 289263000.0% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' EBT Margin is 60.53%, which was up 4627600.0% from 191.52% recorded in Q2 2025.
  • Phathom Pharmaceuticals' EBT Margin's 5-year high stood at 1473.65% during Q1 2022, with a 5-year trough of 11665.1% in Q4 2023.
  • For the 4-year period, Phathom Pharmaceuticals' EBT Margin averaged around 1258.89%, with its median value being 221.33% (2025).
  • Per our database at Business Quant, Phathom Pharmaceuticals' EBT Margin tumbled by -122374500bps in 2023 and then skyrocketed by 114139600bps in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' EBT Margin stood at 572.35% in 2022, then tumbled by -2138bps to 11665.1% in 2023, then soared by 98bps to 251.15% in 2024, then surged by 76bps to 60.53% in 2025.
  • Its last three reported values are 60.53% in Q3 2025, 191.52% for Q2 2025, and 330.64% during Q1 2025.